Syngene International Ltd. · NSE:SYNGENE
Syngene International — Q3 FY26 Earnings Presentation
17 slides from Syngene International's earnings presentation, Jan 23, 2026
Slide 1: Syngene International Q3 FY26 Earnings Call
Syngene International Q3 FY26 Earnings Call 23rd January 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 3: CEO Remarks
CEO Remarks Peter Bains Managing Director & CEO Syngene International Limited Putting Science to Work 3
Slide 4: Q3FY26 Performance
Q3FY26 Performance Sales Split (Q3 FY26) Revenue from Operations INR 917 Cr ( 3% Y-o-Y | 1% sequentially) 34% Operating EBITDA & Margin Research Operating EBITDA INR 209 Cr ( - 26 % Y-o-Y, 5% sequentially) Services Operating EBITDA Margin 23% 66% CDMO business Reported PAT (before exceptional item)
Slide 5: Q3 performance impacted by single commercial stage product in large molecule business
Q3 performance impacted by single commercial stage product in large molecule business The key variable impacting our 3rd quarter performance has been the ongoing impact related to a single commercial stage product from our largest large molecule biologics customer Putting Science to Work 5
Slide 6: Steady underlying growth across all platforms
Steady underlying growth across all platforms • Research Services business continued to secure new customers and contracts across our discovery and our translational and clinical research programs • CDMO saw increased utilization at small-molecule sites, while large-molecule facilities remain attrac
Slide 7: Segment Highlights: Research Services
Segment Highlights: Research Services BMS collaboration extended : Longest-standing partnership with BMS of more than 25 years extended through to 2035; a strategic ten-year horizon to further develop and expand this unique, long- standing collaboration. Expanded advanced chemistry capabilities with
Slide 8: Segment Highlights: CDMO Services
Segment Highlights: CDMO Services Commissioned a new commercial-scale facility for liquid-filled hard gelatin capsules, enhancing the Oral Solid Dosage platform Process and equipment validation completed at the Bayview facility in the U.S., with hiring underway to support operations as planned. Put
Slide 9: CEO's Concluding Remarks
CEO’s Concluding Remarks Differentiated science, strong client relationships, and a diversified Research Services–CDMO model drive resilience and growth Ongoing investments in technology, AI, and capacity strengthen our offering for a growing customer base Putting Science to Work 9
Slide 10: CFO Remarks
CFO Remarks Deepak Jain Chief Financial Officer Syngene International Limited Putting Science to Work 10
Slide 11: Q3 FY26 Performance
Q3 FY26 Performance Q3 FY26 Revenue from Operations (INR Cr) 1000 Q3 FY26 growth -3% Y-o-Y ; 1% sequential growth (reported currency) 944 950 -7% Y-o-Y (constant currency) 917 • Steady performance in Research business led by volume 900 improvement in discovery business • CDMO business affected due o
Slide 12: Costs and Profitability: Q3 FY26
Costs and Profitability : Q3 FY26 % of Revenue from operations Reported PAT before exceptional items down 44% Y-o-Y (INR Cr) Q3 FY25 Q3 FY26 Y-o-Y Change 131 Operating EBITDA Margin 30% 23% -(724bps) Raw material cost 25% 25% -3% Q3 FY25 Q3 FY26 Staff cost 29% 33% 8% 73 Other Direct cost 3% 3% 2% Ot
Slide 13: Capex Summary: USD 9 Mn Invested in Q3 FY26
Capex Summary: USD 9 Mn Invested in Q3 FY26 Capex Spend (%) ~15% ~50% Q3 FY26 ~35% Research CDMO Others Putting Science to Work 13
Slide 14: 9-Month Performance
9-Month Performance 9M FY26 Revenue from Operations (INR Cr) % of Revenue from operations Reported PAT before exceptional Y-o-Y items down 22% y-o-y 9M FY25 9M FY26 Change 2800 Operating EBITDA (INR Cr) 2,702 27% 23% ~(384 bps) 292 2700 Margin 2,624 2600 Raw material cost 27% 25% -3% 227 2500 Staff
Slide 15: Guidance for Full Year FY26 revised
Guidance for Full Year FY26 revised Overall Syngene FY26 Guidance given New guidance Revenue from Ops Growth Mid Single digit -3% to -5% Operating EBITDA Margin Mid 20s 22% to 23% PAT growth before exceptions Negative Negative Capex (USD Mn) 55 45 Putting Science to Work 15
Slide 16: Q&A
Q&A Putting Science to Work Putting Science to Work
Slide 17: Putting Science to Work
© 2026 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the trademark
Syngene International — Q3 FY26 Earnings Presentation on 6ix